WB, IP
H Mk
Endogenous
26
Rabbit
#P04183
7083
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Monkey
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly213 of human TK1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Thymidine kinases play a critical role in generating the DNA synthetic precursor deoxythymidine triphosphate (dTTP) by catalyzing the phosphotransfer of phosphate from ATP to deoxythymidine (dT) and thymidine (T) in the cell. There are two known thymidine kinases, cytoplasmic thymidine kinase 1 (TK1) and mitochondrial thymidine kinase 2 (TK2) (1,2). Unlike TK2, which is not modulated by the cell cycle, TK1 expression and activity is regulated in a cell cycle-dependent manner, accumulating during G1-phase to peak levels in S-phase before being degraded prior to cell division (3,4). Stability, but not activity, may be regulated via phosphorylation of TK1 at Ser13 by Cdc2 and/or Cdk2, but the precise mode of regulation remains elusive (5). These observations indicate that TK1 might be a useful marker of cell proliferation; however, recent studies have shown that TK1 plays a more significant role in the DNA damage response (6). Genotoxic stress promotes increased TK1 expression and kinase activity resulting in reduced cellular apoptosis and enhanced DNA repair efficiency (6). More importantly, numerous studies show that TK1 expression and activity are upregulated during neoplasia and disease progression in humans, and increased serum levels of TK1 correlate with poor prognosis and decreased survival in patients with various types of advanced tumors (7-12).
- Aufderklamm, S. et al. (2012) Cancer Lett 316, 6-10.
- Munch-Petersen, B. (2010) Nucleosides Nucleotides Nucleic Acids 29, 363-9.
- Bello, L.J. (1974) Exp Cell Res 89, 263-74.
- Littlefield, J.W. (1966) Biochim Biophys Acta 114, 398-403.
- Chang, Z.F. et al. (1998) J Biol Chem 273, 12095-100.
- Chen, Y.L. et al. (2010) J Biol Chem 285, 27327-35.
- Hannigan, B.M. et al. (1993) Cancer Biother 8, 189-97.
- Pan, Z.L. et al. (2010) J Cancer Res Clin Oncol 136, 1193-9.
- Chen, Y. et al. (2010) Int J Clin Oncol 15, 359-68.
- Konoplev, S.N. et al. (2010) Am J Clin Pathol 134, 472-7.
- Xu, Y. et al. (2012) Tumour Biol 33, 475-83.
- Alegre, M.M. et al. (2012) J Oncol 2012, 575647.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.